Zaltrap
Zaltrap ingredients
| Active ingredient | Strength |
|---|---|
| Aflibercept | 200 mg/8mL, 100 mg/4mL |
What Zaltrap is used for
The FDA lists the approved uses on the official label (below). In the EU, aflibercept is approved as Zaltrap for:
Treatment of metastatic colorectal cancer (MCRC).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Zaltrap
- Generic name
- Ziv-aflibercept
- Made by
- sanofi-aventis U.S. LLC
- Forms
- Solution, Concentrate
- Given
- Intravenous
- Drug class
- Vascular Endothelial Growth Factor Inhibitor
- FDA approval
- Biologic licence (BLA) BLA125418
- On the US market since
- 2012
Official information
- Zaltrap prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Ziv-aflibercept)
In India
- Aflibercept: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zaltrap?
Zaltrap (Ziv-aflibercept) is a cancer medicine made by sanofi-aventis U.S. LLC, approved by the US FDA.
What are the ingredients of Zaltrap?
Zaltrap contains Aflibercept (200 mg/8mL, 100 mg/4mL).
Is Zaltrap approved in Europe?
The same active substance is approved in the EU as Zaltrap.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA